Related Experiment Video
Updated: Mar 29, 2026

05:31
Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles
Published on: January 26, 2024
1.5K
Clinical and Biomarkers Difference in Prepartum and Postpartum Eclampsia
Yifru Berhan1, Gezahegn Endeshaw1
1College of Medicine and Health Sciences, Hawassa University, Ethiopia.
Ethiopian Journal of Health Sciences
|December 4, 2015
Summary
Eclampsia incidence is high, with distinct clinical and biomarker differences between prepartum and postpartum cases. Postpartum eclampsia is more common in multiparous, adult women with abnormal biomarkers.
Area of Science:
- Obstetrics and Gynecology
- Maternal-Fetal Medicine
- Perinatology
Background:
- Limited research exists on clinical features and biological markers differentiating prepartum and postpartum eclampsia.
- Eclampsia remains a significant concern in maternal health globally.
Purpose of the Study:
- To compare clinical features and biological markers associated with prepartum versus postpartum eclampsia.
- To understand the distinct profiles of women experiencing eclampsia before and after delivery.
Main Methods:
- A comparative analysis of 361 eclamptic women admitted to three teaching hospitals (2008-2013).
- Evaluation of clinical and biological variables in relation to eclampsia timing (prepartum vs. postpartum).
Main Results:
- Eclampsia incidence was 1.2%, with 71% prepartum and 29% postpartum.
- Prepartum eclampsia: younger, primigravida, hypertensive, symptomatic, proteinuric.
- Postpartum eclampsia: adult, multiparous, anemic, thrombocytopenic, hepatic dysfunction; headache less common.
Conclusions:
- Eclampsia incidence in the study population is among the world's highest.
- Significant differences observed in the clinical and biochemical profiles of prepartum and postpartum eclampsia.
- Postpartum eclampsia is associated with multiparity, adult age, and more frequent biomarker derangements.
Related Concept Videos
Hypertension III: Clinical Manifestations and Diagnostic Studies
714
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
714
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
742
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
742

